X

Trial Profile

Ticagrelor In Coronary microvascular dysfunction (TIC) Program: Anti-anginal Efficacy in Primary Coronary Microvascular Disorders.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ticagrelor (Primary)
Indications Angina pectoris
Focus Therapeutic Use
Acronyms TIC-2

Most Recent Events

22 Mar 2022 Status changed from recruiting to discontinued. Participant recruitment ceased early due to difficulties recruiting during COVID-19, drug expiry and no further funding.
22 Mar 2022 Planned End Date changed from 1 Apr 2019 to 7 Dec 2021.
10 Jul 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com